Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04525183 · ClinicalTrials.gov registry record · NA
REVITALIZE: A Telehealth Intervention for Women With Advanced Ovarian Cancer and PARP Inhibitor-Related Fatigue
A NA study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 49
- Enrollment target
NCT04525183 is a NA study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 49 participants.
The verdict
NCT04525183, a NA study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 49 participants
- Enrollment target
Study Summary
This study is testing whether a 6 week skills-based telehealth intervention can help ovarian cancer patients experiencing PARP inhibitor-related fatigue reduce the impact of fatigue on their daily life and activities.
Interventions
- BEHAVIORAL Enhanced Usual Care (EOC)
- BEHAVIORAL REVITALIZE ACT Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2020-12-02 |
| Est. Completion | 2022-08-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04525183
The ClinicalTrials.gov registry entry for NCT04525183 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Enhanced Usual Care (EOC) is the first listed.
NCT04525183 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04525183 about?
NCT04525183 is a clinical study titled "REVITALIZE: A Telehealth Intervention for Women With Advanced Ovarian Cancer and PARP Inhibitor-Related Fatigue". This study is testing whether a 6 week skills-based telehealth intervention can help ovarian cancer patients experiencing PARP inhibitor-related fatigue reduce the impact of fatigue on their daily life and activities.
What is the current status of trial NCT04525183?
This trial is currently completed. It is a NA study. The enrollment target is 49 participants. The study started on 2020-12-02. Estimated completion is 2022-08-09.
What interventions are being tested in trial NCT04525183?
The interventions under investigation include: Enhanced Usual Care (EOC) (BEHAVIORAL), REVITALIZE ACT Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT04525183?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.